Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Sutro Biopharma, Inc.NASDAQ: STRO

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares declines year over year

Q1 FY2026 weighted avg shares of 130.82K shares fell 98.4% year over year, behind the -22.0% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 98.5% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -98.4% toward the trailing-twelve-month pace of -22.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
130.82K-98.5% QoQ
Last fiscal yearDec 2025
8.5M+10.6% YoY
LTMMar 2026
6.42M-22.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.4%——
1 year+10.6%——
3-year CAGR+18.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
8.5M USD
Year-over-year change
+10.6%
4-year CAGR
+16.5%

Weighted Avg Shares vs competitors

How STRO compares with its peers on the latest reported figures

  • STRO's LTM Mar 2026 weighted avg shares of 6.42M shares is the lowest of the 9 companies compared; the peer median is 58.58M shares.
  • Its year-over-year change of -22.0% is the lowest of 9, against a peer median of +25.9%.
  • Over three fiscal years its annual growth of +18.8% compares with a peer median of +15.9%.
STRO Competitors Peer median
Weighted Avg Shares for STRO and competitors
Company Period LTM YoY 3-year CAGR
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
GUTSFractyl Health, Inc. Common StockLTM Mar 202666.33M +37.1%+16.8%
PLRXPliant Therapeutics, Inc.LTM Mar 202661.49M +1.3%+13.5%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
DTILPrecision BioSciences, Inc.LTM Mar 202612.13M +61.6%+63.6%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding STRO) 58.58M+25.9%+15.9%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.